Houston researchers and clinicians are finding ways to personalize patient care with groundbreaking treatments.
Cancer is one of humanitys greatest health challenges, killing millions of people every year. For decades, treatment for the disease has focused primarily on surgery (removing it) and chemotherapy and radiation therapy (attacking it). While these procedures continue to be essential in a patients overall treatment, new developments with a more personalized approach have gained momentum recently, with some treatments even going so far as to attempt to re-educate the bodys immune system.
Even just a couple of years ago, some of these therapies would have seemed like science fiction, but the field of oncology is progressing with breathtaking speedwith some of the advances happening right here in Houston. From targeted immunotherapies like oncolytic virotherapy (OV) and CAR-T cell therapy to the latest in genetic testing, here are the top innovations that have the potential to dramatically shift the paradigm of cancer care in the coming years.
Over the past decade, immunotherapy has rapidly become what researchers call the fifth pillar of cancer treatment (the first four being surgery, radiation, chemotherapy, and targeted therapies), thanks in part to groundbreaking immunology research led by MD Andersons very own Chair of Immunology, Jim Allison, PhD.
Allison was also a winner of the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T-cell biology and his invention of ipilimumab, the first FDA-approved immune checkpoint inhibitor to treat cancer checkpoint inhibitor to treat cancer. According to the University of Texas MD Anderson Cancer Center, rather than attacking the cancer cells directly (with chemo and radiation), immunotherapy trains our immune system to attack cancer.
Heres how it works: Immune system cells (otherwise known as white blood cells), such as T cells and antigen-presenting cells (APCs), defend and protect the body. APCs act as a patrol, looking for cancer and other diseases, and T cells act as soldiers for the immune system. When an APC finds something suspicious, it sends a signal to the T cell, which multiplies and attacks the suspicious cells. But if T cells dont stop, they can damage healthy cells. A safety switch, called a checkpoint, prevents this. Because cancer is so complex, however, T cells are often turned off before their work is done.
With checkpoint inhibitor drugs (also known as immune systemboosting drugs), the most common type of immunotherapy, those T cells can be prevented from switching off, allowing them to finish their job. And immunotherapy benefits dont stop when the treatment ends; instead, they help the immune system remember cancer, so that T cells can quickly target cancer if it returns.
Immunotherapy is able to effectively treat bladder cancer, head and neck cancers, Hodgkins lymphoma, kidney cancer, nonsmall cell lung cancer, and melanoma. In March of this year, the James P. Allison Institute was launched, a visionary research and innovation hub within MD Anderson designed to foster groundbreaking science, to develop new treatments, and to bring the benefits of immunotherapy to all patients.
Immunotherapy has transformed cancer care over the past decade, but, unfortunately, not all patients benefit equally, says Allison, chair of immunology and director of the Allison Institute. Our goal is to change that.
Viruses are known to be harmful invaders of the body. Normally, we try to avoid viral infections, since viruses can kill healthy cells and cause disease. But some viruses can actually be used to target and infect cancer cells specifically, while leaving nearby healthy cells and tissues intact. These viruses, called oncolytic viruses (OV), can be used as a form ofand catalyst forimmunotherapy.
There are two main ways that OVs help fight cancer. First, the oncolytic viruses kill cancer cells directly when they infect these cells and cause them to burst. Second, when the cancer cells die, they release telltale markers called antigens into the body. These cancer antigens are taken up by cells of the immune system, which then alert our bodies attack cells, the T cells, to look for and kill cancer elsewhere in the body.
Several OVs are in clinical testing. According to Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and MD Anderson, various forms of immunotherapy, such as immune checkpoint blockers, have produced significant benefits, but they only work on roughly 15 percent of cancer patients.
In recent years, a few new cancer therapeutic technologies have really revolutionized cancer treatment. The one Im working on, called cancer viral therapy, has generated a lot of excitement for cancer treatment, Zhang says. Basically, you are combining two frontier cancer treatments [OV and immunotherapy] together to not only increase the benefit for a majority of cancer patients, but enhance the benefit of immunotherapy for cancer patients.
Another huge advantage of OV, Zhang says, is that it is much less toxic than chemotherapy. Those improvements are now being made in Zhangs lab, which received a $1.8 million grant this year from the National Institutes of Health to support his work.
Oncolytic viruses induce a powerful immune response against viral components and tumor antigens, Zhang says, and are a promising strategy for targeting T-cell-poor tumors that are not amenable for immunotherapy.
Another form of immunotherapy treatment, called CAR-T cell therapy, has also generated excitement among researchers and oncologists. This treatment, which induces immune cells to hunt down and kill cancer cells, was declared a success for leukemia patients this year after a 10-year follow-up from two of the first patients treated with CAR-T cells.
The treatment involves removing and genetically altering T cells from cancer patients. The altered cells then produce proteins called chimeric antigen receptors (CARs). Six CAR-T cell therapies have been approved by the Food and Drug Administration to treat blood cancers, and they hold enormous promise for the treatment of solid tumors.
Today, there are hundreds of thousands of people at high risk for cancer who dont know it and who could possibly benefit from targeted therapies. A frustrating point to recognize about immunotherapies has been the inability to predict who will benefit from them and who will not.
While scientists have been able to successfully map humans genetic information to create more personalized therapies, it has now also become possible to analyze the DNA of a persons tumor and use therapies designed to target the specific mutations found. By analyzing a persons individual DNA, physicians are able to identify mutations that put them at high risk for certain kinds of cancer. Patients can then be placed on specific treatments, personalized to them, that are aimed at prevention.
As the largest medical city in the world, Houston is at the forefront of advancing life sciences and setting the standard for the medical field. From Memorial Hermann being one of the nations busiest Level I trauma centers to Houston Methodist establishing itself as a leader in heart and vascular treatments and organ transplants, our hospital systems provide access to some of the finest care anywhere. And now in terms of contemporary cancer care research, institutions like MD Anderson and its network of affiliates across the nation are helping make significant inroads in tackling our greatest health challenge.
For more information on emerging cancer treatments, consult with your medical professional or visit cancer.gov.
Read the original:
How Houston Has Become a Leader in Alternative Cancer Therapies - Houstonia Magazine
- Vascular Cell and Molecular Biology | Center for Vascular Biology | Weill Cornell ... - April 13th, 2018 [April 13th, 2018]
- APVBO-Asia Pacific Vascular Biology Organization Conference - April 18th, 2018 [April 18th, 2018]
- Vascular Biology Conferences | Vascular Surgery ... - May 5th, 2018 [May 5th, 2018]
- Vascular Discovery: From Genes to Medicine - May 7th, 2018 [May 7th, 2018]
- 2019 Vascular Cell Biology Conference GRC - May 26th, 2018 [May 26th, 2018]
- Biology 211: Taxonomy of Flowering Plants - June 7th, 2018 [June 7th, 2018]
- esm-evbo2019.org - Menu - July 27th, 2018 [July 27th, 2018]
- Vascular Biology | Pulmonary, Allergy, Sleep & Critical ... - November 16th, 2018 [November 16th, 2018]
- Lower vascular plant | biology | Britannica.com - November 18th, 2018 [November 18th, 2018]
- Vascular Biology - NAVBO - November 20th, 2018 [November 20th, 2018]
- 2019 Cerebral Vascular Biology Conference - cvent.com - November 21st, 2018 [November 21st, 2018]
- PPARs and Their Emerging Role in Vascular Biology ... - November 26th, 2018 [November 26th, 2018]
- Vascular Biology Chicago Medicine - November 30th, 2018 [November 30th, 2018]
- Vascular Biology | Society for Vascular Surgery - November 30th, 2018 [November 30th, 2018]
- Vascular Biology 2018 - NAVBO - December 19th, 2018 [December 19th, 2018]
- Vascular Biology 2019 - NAVBO - December 20th, 2018 [December 20th, 2018]
- Vascular Biology - January 22nd, 2019 [January 22nd, 2019]
- pvb2019.org Plant Vascular Biology Conference 2019 - January 31st, 2019 [January 31st, 2019]
- Plant Physiology | Basic Biology - March 12th, 2019 [March 12th, 2019]
- Awards - esm-evbo2019.org - April 23rd, 2019 [April 23rd, 2019]
- Medication and Exercise to Prevent Muscle Loss - Next Avenue - September 24th, 2019 [September 24th, 2019]
- A Snail as Fast as a Bullet, and Other Darwin-Defying Marvels - Discovery Institute - September 24th, 2019 [September 24th, 2019]
- Nature up close: Life in the Humboldt Penguin National Reserve - CBS News - September 24th, 2019 [September 24th, 2019]
- Oklahoma new hires and promotions announced - Oklahoman.com - September 24th, 2019 [September 24th, 2019]
- Quinn Capers IV, MD - TCTMD - September 24th, 2019 [September 24th, 2019]
- Cardiovascular Repair And Reconstruction Devices Market Global Industry Insights by Top Vendors, Growth, Revenue and Forecast Outlook 2019-2025 -... - September 26th, 2019 [September 26th, 2019]
- Four health projects at Boston Childrens Hospital that could help adults - The Boston Globe - September 30th, 2019 [September 30th, 2019]
- Research Officer/ Postdoctoral Researcher - The Conversation AU - October 16th, 2019 [October 16th, 2019]
- UNSW skin cancer researcher Levon Khachigian hit with string of retractions - ABC News - October 16th, 2019 [October 16th, 2019]
- Michal Wszola: We Expect to Transplant the Bioprinted Bionic Pancreas in Three to Five Years - 3DPrint.com - October 24th, 2019 [October 24th, 2019]
- 'The Blob': This mysterious 'smart' slime can solve puzzles and make decisions - CNBC - October 24th, 2019 [October 24th, 2019]
- University of Maryland and DOD collaborate to study Tick-borne Infections using 3-D models of human blood vessels - Outbreak News Today - November 19th, 2019 [November 19th, 2019]
- Submerged Vegetation Mirrors Coast's Health - Coastal Review Online - November 19th, 2019 [November 19th, 2019]
- Another health warning for e-cigarette users that has nothing to do with lung disease - MarketWatch - November 19th, 2019 [November 19th, 2019]
- E-Cigarettes Take a Dangerous Toll on Heart Health - DocWire News - November 19th, 2019 [November 19th, 2019]
- Vascular biology Department of Surgery College of ... - November 19th, 2019 [November 19th, 2019]
- US Nobel laureates tell us what they think about cancer research, moonshots, the dark side, funding, meritocracy, herd mentality, Trump, and joy - The... - November 21st, 2019 [November 21st, 2019]
- Growing Organs in the Lab: One Step Closer to Reality - BioSpace - November 21st, 2019 [November 21st, 2019]
- Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock - Business Wire - November 21st, 2019 [November 21st, 2019]
- Another Study Suggests E-cigarettes Hurt Heart Health More Than Regular Cigarettes - Science Times - November 21st, 2019 [November 21st, 2019]
- Cleveland Clinic awarded $12 million by NIH to study the link between gut microbes and heart disease - Crain's Cleveland Business - November 21st, 2019 [November 21st, 2019]
- JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD) - Yahoo Finance - November 27th, 2019 [November 27th, 2019]
- Germ-free lungs of newborn mice are partially protected against hyperoxia - The Mix - November 27th, 2019 [November 27th, 2019]
- Bethesda Health Physician Group Welcomes Fellowship-Trained Endocrine Surgeon Jessica L. Buicko, MD, to Its Team - The Boca Raton Tribune - November 27th, 2019 [November 27th, 2019]
- 9 Harvard researchers named AAAS Fellows Harvard - Harvard Gazette - November 27th, 2019 [November 27th, 2019]
- Top Technical Advances of 2019 - The Scientist - December 29th, 2019 [December 29th, 2019]
- Growing up Tyrannosaurus rex: Osteohistology refutes the pygmy Nanotyrannus and supports ontogenetic niche partitioning in juvenile Tyrannosaurus -... - January 2nd, 2020 [January 2nd, 2020]
- UCC currently taking applicants for 21 jobs with some incredible pay - Cork Beo - January 2nd, 2020 [January 2nd, 2020]
- Vascular Biology | Surgery Research | Michigan Medicine ... - January 2nd, 2020 [January 2nd, 2020]
- Sandy Bottom wetlands to receive protection for 'national ecological significance' - Citizen Times - January 14th, 2020 [January 14th, 2020]
- Why biotech is a boon for patients and investors - Spear's WMS - January 14th, 2020 [January 14th, 2020]
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related... - January 14th, 2020 [January 14th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 Dagoretti News - Dagoretti News - January 18th, 2020 [January 18th, 2020]
- Scientists revealed the oldest known scorpion on Earth - Tech Explorist - January 18th, 2020 [January 18th, 2020]
- How biology creates networks that are cheap, robust, and efficient - Penn: Office of University Communications - January 18th, 2020 [January 18th, 2020]
- Genome editing heralds new era of disease research, therapy - The Augusta Chronicle - January 18th, 2020 [January 18th, 2020]
- Research Fellow in Vascular Stem Cell Biology job with QUEENS UNIVERSITY BELFAST | 195527 - Times Higher Education (THE) - February 10th, 2020 [February 10th, 2020]
- More than skin deep: the latest innovation in 3D printing - Med-Tech Innovation - February 10th, 2020 [February 10th, 2020]
- Examining the link between menopause and heart disease risk - Medical News Bulletin - February 10th, 2020 [February 10th, 2020]
- Women Face an Increased Risk of Heart Disease With AgeRunning Can Help - runnersworld.com - February 12th, 2020 [February 12th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 - Galus Australis - February 15th, 2020 [February 15th, 2020]
- Valentine's Day Matters of the Heart, Biopharma-Style - BioSpace - February 15th, 2020 [February 15th, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Sharon - February 22nd, 2020 [February 22nd, 2020]
- UI at 150 & Beyond: 'The Quad was the best no matter what the weather' - Champaign/Urbana News-Gazette - February 22nd, 2020 [February 22nd, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Dedham - February 23rd, 2020 [February 23rd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Wareham - March 22nd, 2020 [March 22nd, 2020]
- 'Little Foot' skull reveals how this more than 3 million year old human ancestor lived - HeritageDaily - March 22nd, 2020 [March 22nd, 2020]
- It's Not Only About Neurons - The Good Men Project - March 22nd, 2020 [March 22nd, 2020]
- Who is Sir Patrick Vallance and what is his role in government during coronavirus outbreak? - The Scottish Sun - March 22nd, 2020 [March 22nd, 2020]
- University of Washington Pathology Professor Dies of COVID-19 - The Scientist - March 22nd, 2020 [March 22nd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Rochester - March 23rd, 2020 [March 23rd, 2020]
- Ancient human ancestor 'Little Foot' probably lived in trees, new research finds - WBAP News/Talk - March 23rd, 2020 [March 23rd, 2020]
- Study shows similarity in anti-VEGF injection intervals for wet AMD - Ophthalmology Times - March 25th, 2020 [March 25th, 2020]
- aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform - BioSpace - March 25th, 2020 [March 25th, 2020]
- Health researchers find solution to life-threatening side effect - Mirage News - March 25th, 2020 [March 25th, 2020]
- European Vascular Biology Organisation | Advancing human ... - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Program | Boston Children's Hospital - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Research Program | Johns Hopkins ... - March 25th, 2020 [March 25th, 2020]
- Anatomy of a heatwave: how Antarctica recorded a 20.75C day last month - The Conversation AU - April 1st, 2020 [April 1st, 2020]
- Who is Sir Patrick Vallance and is he speaking at todays government coronavirus press briefing? - The Sun - April 1st, 2020 [April 1st, 2020]